Dmc.Hm
DMC.HM is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. DMC.HM is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DMC.HM is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
DMC.HM maintains a strong capital structure with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is robust, with a current ratio of 7.47, suggesting it has ample short-term assets to cover its liabilities. Additionally, DMC.HM holds $50 billion in cash and equivalents, which supports its operational flexibility and capacity to fund strategic initiatives.
Profitability metrics for DMC.HM are strong, with a return on equity (ROE) of 11.75% and a return on assets (ROA) of 10.36%. These figures exceed the typical benchmarks for the pharmaceutical industry, indicating efficient use of equity and assets to generate returns. The company's operating income of $244.38 billion and net income of $198.40 billion further underscore its profitability.
Geographically and segment-wise, DMC.HM's revenue is not explicitly broken down in the available data, but the company's exposure is inferred to be broad given the global nature of the pharmaceutical industry. The absence of detailed segment data suggests a need for further analysis to understand revenue concentration and geographic risk.
Looking ahead, DMC.HM is positioned for continued growth, with strong free cash flow generation of $94.24 billion and capital expenditures of -$36.70 billion, indicating a focus on cost efficiency and asset optimization. The company's operating cash flow of $161.35 billion supports its ability to fund operations and invest in future growth.
Risk factors for DMC.HM are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's low dilution potential and strong liquidity position reduce the likelihood of equity dilution in the near term. However, the pharmaceutical industry is subject to regulatory and geopolitical risks, which could impact future operations and profitability.
Recent events and filings for DMC.HM do not indicate any significant changes in its financial or operational status. The company's strong financial performance and low risk profile suggest a stable and predictable business environment.
- DMC.HM has a robust liquidity position with a current ratio of 7.47 and $50 billion in cash and equivalents.
- The company's profitability is strong, with ROE and ROA of 11.75% and 10.36%, respectively.
- DMC.HM has no long-term debt, reducing its financial risk and enhancing its flexibility.
- The company's free cash flow and operating cash flow are substantial, supporting future growth and operational needs.
- No immediate liquidity or dilution risks are identified, indicating a stable capital structure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- DMC.HM Market data — financials · 2026-05-27
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shares outstanding (annual): 47.37MUnknown
- Net income (annual): USD 93.5MUnknown
- Interest expense (annual): USD 11.2MUnknown
- Shareholders' equity (annual): USD 2.02BUnknown
- Total assets (annual): USD 3.06BUnknown
- Pre-tax income (annual): USD 130.9MUnknown
- Operating cash flow (annual): USD 245.1MUnknown
- EPS (basic) (annual): USD-PER-SHARES 2Unknown
- Current liabilities (annual): USD 529.3MUnknown
- Operating income (annual): USD 137.4MUnknown
- Revenue (annual): USD 4.32BUnknown
- Cost of revenue (annual): USD 3.92BUnknown
- Total liabilities (annual): USD 1.03BUnknown
- Cash & equivalents (annual): USD 35.7MUnknown
- Current assets (annual): USD 1.14BUnknown
- EPS (diluted) (annual): USD-PER-SHARES 2Unknown
- Gross profit (annual): USD 399.1MUnknown
- Net income (annual): USD 141.6MUnknown
- Revenue (annual): USD 4.28BUnknown
- Current liabilities (annual): USD 533.1MUnknown
- Cash & equivalents (annual): USD 32.6MUnknown
- Shares outstanding (annual): 47.94MUnknown
- Total liabilities (annual): USD 1.09BUnknown
- Pre-tax income (annual): USD 170.7MUnknown